Fasturtec

Fasturtec

rasburicase

Manufacturer:

sanofi-aventis

Distributor:

DKSH
Concise Prescribing Info
Contents
Rasburicase
Indications/Uses
Treatment & prophylaxis of acute hyperuricaemia in order to prevent acute renal failure, in patients w/ haematological malignancy w/ a high tumour burden & at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy.
Dosage/Direction for Use
0.2 mg/kg daily as a once daily 30-min IV infusion for up to 7 days.
Contraindications
Hypersensitivity to uricases. G6PD deficiency & other cellular metabolic disorders known to cause haemolytic anaemia.
Special Precautions
Monitor closely for onset of allergic-type undesirable effects eg, anaphylaxis. History of atopic allergies. Discontinue treatment immediately & permanently if severe hypersensitivity reactions, methaemoglobinaemia or haemolysis develops. Not directly effective in the treatment of hyperphosphataemia, hyperkalaemia & hypocalcaemia. Not recommended in women of childbearing potential not using contraception. Pregnancy & lactation.
Adverse Reactions
Headache; diarrhoea, vomiting, nausea, fever. Allergy/allergic reactions (rashes & urticaria).
ATC Classification
V03AF07 - rasburicase ; Belongs to the class of detoxifying agents used in antineoplastic treatment.
Presentation/Packing
Form
Fasturtec soln for infusion 1.5 mg/mL
Packing/Price
3 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in